Logo

Atara Biotherapeutics, Inc.

ATRA

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors… read more

Healthcare

Biotechnology

11 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$8.55

Price

+2.03%

$0.17

Market Cap

$77.037m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-636.8%

EBITDA Margin

-803.3%

Net Profit Margin

-595.5%

Free Cash Flow Margin

-636.8%

EBITDA Margin

-803.3%

Net Profit Margin

-595.5%

Free Cash Flow Margin
Revenue

$23.139m

-80.8%

1y CAGR

+439.0%

3y CAGR

+307.6%

5y CAGR
Earnings

-$9.467m

-129.0%

1y CAGR

+26.1%

3y CAGR

+14.4%

5y CAGR
EPS

-$0.67

-126.1%

1y CAGR

+26.3%

3y CAGR

+15.6%

5y CAGR
Book Value

-$37.312m

$19.997m

Assets

$57.309m

Liabilities

$10.090m

Debt
Debt to Assets

50.5%

-1.8x

Debt to EBITDA
Free Cash Flow

-$25.875m

+49.2%

1y CAGR

+46.6%

3y CAGR

+42.3%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases